Entering the U.S. Market Requires More Than a Distributor
The United States can represent one of the largest opportunities for a diagnostics or MedTech company — and one of the easiest markets in which to make expensive assumptions. Vernon Row helps international companies translate successful products, technologies and commercial models into the realities of the U.S. healthcare market — before committing significant capital to infrastructure, distribution or launch.
The commercial questions behind a defensible U.S. entry.
Is there a commercially attractive U.S. market?
Which customer segments should we target first?
How will U.S. reimbursement and payment pathways affect adoption and pricing?
Does the product create a compelling economic case for the U.S. customer?
What should we charge?
Should we sell direct, through distribution, or through a hybrid model?
How large does the U.S. commercial organization need to be?
Which accounts and geographies should we prioritize?
What does a realistic 3-year commercialization plan look like?
The Assessment
The U.S. Commercial Readiness Assessment.
A focused executive-level assessment of the market, economics and commercial requirements for entering or expanding in the United States. It is designed for companies deciding whether the U.S. opportunity is commercially attractive, where to focus, how to enter and what must be in place to succeed.
The output is not another market report. It is a decision-oriented commercial-readiness assessment supported by structured research, public market data and source-backed analysis.
The Workstreams
Five strategic areas.
Market & Customer Opportunity
Where the real opportunity sits — by customer segment, site of care and geography — and whether it is large enough to justify the investment.
Reimbursement & Economics
How U.S. payment and reimbursement pathways affect adoption, what the customer can economically justify, and where the economics create barriers or opportunities.
Positioning & Business Model
How the product should be positioned, priced and offered commercially—and which business model best supports adoption.
Route to Market
Whether to build a direct U.S. presence, work through distributors or strategic partners, or use a hybrid model—and which customers and regions to prioritize first.
Commercial Roadmap
The organization, sequencing and milestones required to enter the market and build early commercial traction.
The Deliverables
What management receives.
A concise, decision-oriented package built for an executive audience — not a dense reference document.
- Executive commercial-readiness assessment
- Findings across the five strategic areas
- Key assumptions and confidence levels
- Prioritized actions for U.S. market entry
- Executive readout and discussion
When It Fits
Before building the U.S. organization, build the U.S. commercial case.
The assessment is most valuable when an international company is weighing U.S. entry, preparing for commercialization or questioning where to invest first. It is designed for the period before significant capital is committed — when commercial assumptions can still be tested, reframed or abandoned at relatively low cost.
Specialist expertise, when needed.
Vernon Row focuses on commercial strategy and works alongside regulatory, reimbursement, legal, clinical and other specialist advisors where appropriate.
Evaluate whether the U.S. opportunity justifies the investment.
A brief conversation can clarify where you are in the process and whether a commercial-readiness assessment is the right next step.
Evaluate Your U.S. Opportunity